Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women
Public ClinicalTrials.gov record NCT04766086. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 2B, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE
Study identification
- NCT ID
- NCT04766086
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 306 participants
Conditions and interventions
Conditions
Interventions
- Multivalent Group B streptococcus vaccine Biological
- Placebo Biological
- Tetanus, diphtheria, and acellular pertussis vaccine Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 49 Years
- Sex
- Female
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 11, 2022
- Primary completion
- Apr 26, 2023
- Completion
- Apr 26, 2023
- Last update posted
- May 23, 2024
2022 – 2023
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alliance for Multispecialty Research, LLC | Newton | Kansas | 67114 | — |
| Quality Clinical Research, Inc | Omaha | Nebraska | 68114 | — |
| Alliance for Multispecialty Research, LLC | Las Vegas | Nevada | 89119 | — |
| Accellacare - Raleigh | Raleigh | North Carolina | 27609 | — |
| Accellacare - Wilmington | Wilmington | North Carolina | 28401 | — |
| PriMED Clinical Research | Dayton | Ohio | 45419 | — |
| PriMed Clinical Research | Dayton | Ohio | 45429 | — |
| Lynn Health Science Institute | Oklahoma City | Oklahoma | 73112 | — |
| Alliance for Multispecialty Research, LLC | Knoxville | Tennessee | 37909 | — |
| Benchmark Research | Fort Worth | Texas | 76135 | — |
| DM Clinical Research - Brookline | Houston | Texas | 77081 | — |
| J. Lewis Research, Inc. / Foothill Family Clinic South | Salt Lake City | Utah | 84121 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04766086, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 23, 2024 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04766086 live on ClinicalTrials.gov.